Rheumatoid arthritis management in a patient with deformity is?

Correct Answer: A. Methotrexate with anti-TNF

The presence of deformity in rheumatoid arthritis (RA) indicates established, erosive disease with structural joint damage. This is a critical clinical milestone that mandates aggressive disease-modifying antirheumatic drug (DMARD) therapy combined with biologic agents to halt progression and prevent further irreversible damage. Methotrexate remains the anchor DMARD in India and globally, with proven efficacy in slowing radiographic progression. However, methotrexate monotherapy is insufficient in moderate-to-severe RA with deformity; anti-TNF agents (infliximab, adalimumab, etanercept) are essential additions. The combination of methotrexate + anti-TNF achieves remission or low disease activity in 40–50% of Indian RA patients and significantly reduces the rate of new joint erosions and functional decline. This is the standard-of-care approach per Indian rheumatology guidelines and EULAR recommendations. Steroids, while useful for short-term inflammation control, do not modify disease course and carry long-term toxicity (osteoporosis, infections, metabolic complications)—particularly problematic in Indian populations with high tuberculosis prevalence. Early aggressive DMARD + biologic therapy is the only strategy proven to prevent further deformity progression and preserve joint function.

Why the other options are wrong

B. Methotrexate with steroids — While methotrexate is correct, steroids are not disease-modifying and do not address the underlying inflammatory cascade driving erosive disease. Steroids alone cannot prevent progression of deformity and carry significant long-term toxicity (immunosuppression, TB reactivation risk in India, osteoporosis). Anti-TNF agents are superior to steroids for halting structural damage in established RA with deformity. C. Steroids — Steroids are anti-inflammatory but not disease-modifying; they do not slow radiographic progression or prevent new erosions. In established RA with deformity, monotherapy with steroids is inadequate and exposes patients to serious adverse effects (TB reactivation, infections, adrenal suppression). This represents outdated RA management and violates current Indian and international guidelines. D. Steroids only after NSAIDs fail — This reflects a stepwise, delayed approach that is contraindicated in RA with deformity. Both NSAIDs and steroids are symptomatic agents only; neither modifies disease course. Delaying DMARD + biologic therapy in the presence of structural damage allows continued erosion and irreversible joint destruction. Early aggressive therapy is the evidence-based standard.

High-Yield Facts

Mnemonics

DMARD Escalation in RA with Deformity Deformity = Do not delay → Methotrexate + Anti-TNF Required. Skip steroids; they are not disease-modifying. Steroids in RA: What They DON'T Do Steroids = Symptoms only (not Structure-modifying). They control pain/swelling but do NOT prevent erosions or deformity progression.

NBE Trap

NBE may lure students into choosing "methotrexate + steroids" by emphasizing the role of methotrexate while overlooking that steroids are not disease-modifying and are inferior to anti-TNF agents in preventing structural damage in established RA. The trap exploits confusion between symptomatic and disease-modifying therapy.

Clinical Pearl

In Indian clinical practice, many RA patients present late with established deformity due to delayed diagnosis and limited access to biologics. Once deformity is evident, the goal shifts from remission induction to halting further progression—methotrexate + anti-TNF is the only combination with proven efficacy to reduce erosion rate and preserve remaining joint function. Steroids alone will mask symptoms while disease silently progresses.

_Reference: Harrison Ch. 313 (Rheumatoid Arthritis); Robbins Ch. 6 (Inflammatory Joint Disease); Indian Rheumatology Association Guidelines on RA Management_